LAUSR

&NA; Synthetic macrocyclic peptides with natural and unnatural amino acids have gained considerable attention from a number of pharmaceutical/biopharmaceutical companies in recent years as a promising approach to drug discovery, particularly for targets involving protein–protein or protein–peptide interactions. Analytical scientists charged with characterizing these leads face multiple challenges including dealing with a class of complex molecules with the potential for multiple isomers and variable charge states and no established standards for acceptable analytical characterization of materials used in drug discovery. In addition, due to the lack of intermediate purification during solid phase peptide synthesis, the final products usually contain a complex profile of impurities. In this paper, practical analytical strategies and methodologies were developed to address these challenges, including a tiered approach to assessing the purity of macrocyclic peptides at different stages of drug discovery. Our results also showed that successful progression and characterization of a new drug discovery modality benefited from active analytical engagement, focusing on fit‐for‐purpose analyses and leveraging a broad palette of analytical technologies and resources. HighlightsColumn screening and temperature‐dependent HPLC study.API content estimation by incorporating q‐NMR and HPLC analysis.Tiered analytics to purity assessment at different drug discovery stages.Analytical characterization of macrocyclic peptide development candidates.Batch to batch consistency of scale‐up lots for macrocyclic peptide development candidates.